Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: A pilot study on a series of 56 patients
Open Access
- 2 March 2010
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 78B (3) , 154-168
Abstract
A heterogeneous spectrum of immunophenotypic abnormalities have been reported in myelodysplastic syndromes (MDS). However, most studies are restricted to the analysis of CD34+ cells and/or other major subsets of CD34− cells, frequently not exploring the diagnostic and prognostic impact of immunophenotyping.Methods: We propose for the first time an immunophenotypic score (IS) based on the altered distribution and immunophenotypic features of maturing/mature compartments of bone marrow (BM) hematopoietic cells in 56 patients with MDS that could contribute to a refined diagnosis and prognostic evaluation of the disease.Results: Although MDS‐associated phenotypes were detected in reactive BM, the overall immunophenotypic profile of BM cells allowed an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected per patient were simultaneously considered in the proposed IS. Interestingly, increasingly higher IS were found among patients with MDS showing adverse prognostic factors and in low‐ versus high‐grade cases. The most informative prognostic factors included the number of CD34+ cells, presence of aberrant CD34−/CD117+ precursors, decreased mature neutrophils and CD34− erythroid precursors, and increased numbers of CD36−/lo erythroid precursors; in addition, the IS was an independent prognostic factor for overall survival.Conclusions: Assessment of immunophenotypic abnormalities of maturing/mature BM cells allows an efficient discrimination between MDS and both normal and reactive BM, once the number and degree of severity of the abnormalities detected are simultaneously scored. Interestingly, progressively higher IS were found among patients with MDS with adverse prognostic features and shorter overall survival. © 2010 Clinical Cytometry SocietyKeywords
This publication has 37 references indexed in Scilit:
- Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromesHaematologica, 2009
- A probabilistic approach for the evaluation of minimal residual disease by multiparameter flow cytometry in leukemic B‐cell chronic lymphoproliferative disordersCytometry Part A, 2008
- Multiparameter Flow Cytometric Analysis Reveals Low Percentage of Bone Marrow Hematogones in Myelodysplastic SyndromesAmerican Journal of Clinical Pathology, 2008
- A new disease categorization of low-grade myelodysplastic syndromes based on the expression of cytopenia and dysplasia in one versus more than one lineage improves on the WHO classificationLeukemia, 2007
- Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndromeLeukemia, 2006
- Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasiaCytometry Part B: Clinical Cytometry, 2006
- Pathobiology, classification, and diagnosis of myelodysplastic syndromeBest Practice & Research Clinical Haematology, 2004
- Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31Leukemia, 2003
- Evidence for expression of early myeloid antigens in mature, non-blast myeloid cells in myelodysplasiaAmerican Journal of Hematology, 2003
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982